Just listened to ENTA's Leerink talk, and all questions were about the science and timing of the drugs and partnerships; no one asked what they would do with the money. But, based on Luly's comment at the annual meeting to the effect that they wished to remain a research shop, I would guess that they will pay most of it to the shareholders in the form of dividends.
Market Data 
Markets 
AI
